(Q35989815)

11 August 2017

1 reference

title

Gefitinib therapy for non-small cell lung cancer (English)

1 reference

11 August 2017

1 reference

Ariel Birnbaum

1

1 reference

11 August 2017

Neal Ready

series ordinal

2

1 reference

11 August 2017

publication date

1 January 2005

1 reference

Current Treatment Options in Oncology

11 August 2017

published in

1 reference

11 August 2017

volume

6

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

75-81

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-005-0015-0

11 August 2017

exact match

0 references

cites work

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

ErbB-targeted therapeutic approaches in human cancer

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

12 December 2020

Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

Severe acute interstitial pneumonia and gefitinib

1 reference

12 December 2020

10.1007/S11864-005-0015-0

Identifiers

DOI

1 reference

11 August 2017

1 reference